Many studies show that T cells infiltrating tumor tissue have the ability to specifically recognize tumor cells. Treatment of cancer patients, using the patient's own T cells isolated from tumor tissue, has been shown to result in a more 70% durable response rate and we intend to offer a similar option to patients with cancer. The immune cells are grown in a controlled and sterile environment and activated to be more effective against cancer cells. Complete tumor analysis is performed with the intention of identifying the patient's mutation which acts as anti-tumor targeting TAAs (tumor associated antigens). The second layer of the approach uses transgenic T cells which exploit the transfer of T cell receptors (targeting so-called general tumor antigens, which are only found in tumors, not yet in healthy tissue) or use specific anti-cancer targeting antibodies (e.g. targeting mesothelin or FGVRvIII, "CARs") fused with molecules that enable T cells to kill cancer cells. The aim is to identify the best tailored treatment and the best strategy to equip the patient's immune cells for the destruction of tumor cells: the "personalized therapy" using a detailed evaluation of the patient's tumor and the patient's immune cells to offer the best approach to immunological treatment.